Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;17(2):49-60.
doi: 10.1049/nbt2.12102. Epub 2022 Nov 7.

Nano-gold micelles loaded Dox and Elacridar for reversing drug resistance of breast cancer

Liu-Jing Wen  1 , Yue-Sheng Wang  2 , Jie Zhang  1
Affiliations

Nano-gold micelles loaded Dox and Elacridar for reversing drug resistance of breast cancer

Liu-Jing Wen et al. IET Nanobiotechnol. 2023 Apr.

Abstract

The aim of this study was to provide a new effective carrier for rescuing the sensitivity of drug-resistant in breast cancer cells. Nano-gold micelles loaded with Dox and Elacridar (FP-ssD@A-E) were chemically synthesised. With the increase in the amount of Dox and Elacridar, the encapsulation rate of FP-ssD@A-E gradually increased, and the drug loading rate gradually decreased. FP-ss@A-E had a sustained-release effect. Dox, Elacridar, FP-ss@AuNPs, and FP-ssD@A-E significantly improved cell apoptosis, in which, FP-ssD@A-E was the most significant. FP-ssD@A-E significantly decreased the cell viability and improved the Dox uptake. The levels of VEGFR-1, P-gp, IL-6, and i-NOS were significantly decreased after Dox, Dox + Elacridar, FP-ss@AuNPs, and FP-ssD@A-E treatment. It was worth noting that FP-ssD@A-E had the most significant effects. The prepared FP-ssD@A-E micelles, which were spherical in shape, uniform in particle size distribution, and had good drug loading performance and encapsulation efficiency.

Keywords: breast cancer; doxorubicin; drug loaded hybrid micelles; elacridar; gold nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors report that they have no declarations of interest.

Figures

Scheme 1
Scheme 1
The preparation of P(tBMA)‐P(MMA‐SS‐DOX)
FIGURE 1
FIGURE 1
Chemical structure characterisation of dual drug‐loaded nanomicelles. (a) 1H NMR of MMA‐SS‐NH2, DOX, MMA‐SS‐DOX, and P(tBMA)‐P(MMA‐SS‐Dox). (b) FTIR spectra of DOX, AuNPs, Elacridar, FP‐ss@AuNPs, and FP‐ssD@A‐E. (c) The light absorption values of DOX, AuNPs, Elacridar, FP‐ss@AuNPs, and FP‐ssD@A‐E under different wavelength conditions. (d) The XRD spectra.
FIGURE 2
FIGURE 2
Morphology analysis of dual drug‐loaded nanomicelles. (a) The transmission electron microscope (TEM) test. (b) The dynamic laser light scattering (DLS) assay. (c) The zeta potential of AuNPs, FP‐ss@AuNPs, and FP‐ssD@A‐E.
FIGURE 3
FIGURE 3
Drug release of dual drug‐loaded nanomicelles. (a) The regression equation of the standard curve of DOX was y = 0.65x + 0.00627, and the regression equation of the standard curve of Elacridar was y = 349721x − 97.96. (b) With the increase in the amount of Elacridar and DOX, the encapsulation rate of FP‐ssD@A‐E gradually increased, and the drug loading rate gradually decreased. (c) FP‐ss@A‐E had a sustained‐release effect.
FIGURE 4
FIGURE 4
Cell cytotoxicity in vitro. (a) FP‐ss@AuNPs nanoparticles were non‐cytotoxic. (b−e) Free Dox, Elacridar, and FP‐ssD@A‐E have dose‐dependent toxicity to HBL‐100, MCF‐7, and MCF‐7/MDR cells. Compared with HBL‐100 group, *p < 0.05, **p < 0.01, ***p < 0.001, Compared with MCF‐7 group, #p < 0.05, ##p < 0.01. (f−h) The differences in cell proliferation of HBL‐100, MCF‐7, and MCF‐7/MDR in each group at 2, 8, 24, and 48 h. Compared with free Dox group, *p< 0.05, **p < 0.01, ***p < 0.001.
FIGURE 5
FIGURE 5
FP‐ssD@A‐E improved cell apoptosis
FIGURE 6
FIGURE 6
FP‐ssD@A‐E significantly improved the Dox uptake.
FIGURE 7
FIGURE 7
FP‐ss@AuNPs decreased cytokine level
See this image and copyright information in PMC

References

    1. Zheng, J.L. , et al.: Graphene‐based materials: a new tool to fight against breast cancer. Int. J. Pharm. 603, 120644 (2021). 10.1016/j.ijpharm.2021.120644 - DOI - PubMed
    1. Olsson, A. , Schubauer‐Berigan, M. , Schüz, J. : Strategies of the International Agency for Research on Cancer (IARC/WHO) to reduce the occupational cancer burden. Meditsina Tr. Promyshlennaia Ekol. 61(3), 140–154 (2021). 10.31089/1026-9428-2021-61-3-140-154 - DOI
    1. Esteva, F. , et al.: Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 20(3), e175–e186 (2019) - PubMed
    1. Meng, G.G. , James, B.R. , Skov, K.A. : Porphyrin chemistry pertaining to the design of anti‐cancer drugs; part 1, the synthesis of porphyrins containing meso‐pyridyl and meso‐substituted phenyl functional groups. Can. J. Chem. 72(9), 2447–2457 (1994). 10.1139/v94-241 - DOI
    1. Lamichhane, S. , Lee, S. : Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy. Arch Pharm. Res. 43(1), 118–133 (2020). 10.1007/s12272-020-01204-7 - DOI - PubMed